首页> 外文OA文献 >328 Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003)

【2h】

328 Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003)

机译：328阶段3奥拉帕里布+贝伐单抗与贝伐单抗+氟尿嘧啶的患者在患者中，在第一线Folfox + Bevacizumab（Lynk-003）上没有进展

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Carlos Mayo; Ellen B Gurary; Patricia Marinello;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 328?Phase 3 study of olaparib ± bevacizumab versus bevacizumab fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX bevacizumab (LYNK-003) [J] . Carlos Mayo, Ellen B Gurary, Patricia Marinello Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：328？第3期奥拉帕里布+贝伐单抗与贝伐单抗的氟尿嘧啶患者在第一线Folfox Bevacizumab（Lynk-003）上未能进展
2. Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. [J] . Stefan Madajewicz, David M Waterhouse, Paul S Ritch, Investigational new drugs. . 2012,第2期

机译：贝伐单抗联合亚叶酸，氟尿嘧啶，吉西他滨（FFG）与贝伐单抗联合亚叶酸，氟尿嘧啶，奥沙利铂（FOLFOX4）的多中心随机II期试验作为晚期结直肠癌患者的一线治疗。
3. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Randomised phase-II trial of CAPIRI (capecitabine irinotecan) plus bevacizumab vs FOLFIRI (folinic acid 5-fluorouracil irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) [O] . J Souglakos, N Ziras, S Kakolyris, 2012

机译：CAPIRI（卡培他滨伊立替康）加贝伐单抗与FOLFIRI（亚叶酸5-氟尿嘧啶伊立替康）加贝伐单抗的II期随机试验作为不可切除/转移性结直肠癌（mCRC）患者的一线治疗
7. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis [O] . K. Lesniewski-Kmak, V. Moiseenko, M. Saunders, 2018

机译：II期研究评估Trifluridine / Tipiracil + Bevacizumab和Capecitabine + Bevacizumab在一线不可切入的转移性结肠直肠癌（MCRC）患者中是非有资格进行密集治疗的患者（Tasco1）：主要分析结果

328 Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003)

著录项

引文网络

相似文献

相关主题

期刊订阅